Francasco Patti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5708951/publications.pdf

Version: 2024-02-01

319 papers	11,789 citations	38742 50 h-index	46799 89 g-index
330 all docs	330 docs citations	330 times ranked	9579 citing authors

#	Article	IF	Citations
1	PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study. Journal of Neurology, 2022, 269, 933-944.	3.6	10
2	Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening. Multiple Sclerosis Journal, 2022, 28, 472-479.	3.0	13
3	Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration. Journal of Neurology, 2022, 269, 1463-1469.	3.6	4
4	SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study. Multiple Sclerosis Journal, 2022, 28, 1034-1040.	3.0	37
5	Job satisfaction among physicians and nurses involved in the management of multiple sclerosis: the role of happiness and meaning at work. Neurological Sciences, 2022, 43, 1903-1910.	1.9	8
6	Rituximab for the treatment of multiple sclerosis: a review. Journal of Neurology, 2022, 269, 159-183.	3.6	85
7	Factors driving delayed time to multiple sclerosis diagnosis: Results from a population-based study. Multiple Sclerosis and Related Disorders, 2022, 57, 103361.	2.0	11
8	Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis. Multiple Sclerosis and Related Disorders, 2022, 57, 103385.	2.0	8
9	The effect of air pollution on COVIDâ€19 severity in a sample of patients with multiple sclerosis. European Journal of Neurology, 2022, 29, 535-542.	3.3	8
10	Spinal needle and post-dural puncture headache. Neurological Sciences, 2022, 43, 1467-1468.	1.9	1
11	Changes in John Cunningham Virus Index in Multiple Sclerosis Patients Treated with Different Disease-Modifying Therapies. Current Neuropharmacology, 2022, 20, 1978-1987.	2.9	5
12	COVID-19 Severity in Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	57
13	Real world comparison of teriflunomide and dimethyl fumarate in naÃ¯ve relapsing multiple sclerosis patients: Evidence from the Italian MS register. Multiple Sclerosis and Related Disorders, 2022, 58, 103489.	2.0	2
14	Reliability of televisits for patients with mild relapsingâ€“remitting multiple sclerosis in the COVID-19 era. Neurological Sciences, 2022, , 1.	1.9	3
15	Risk of Getting COVID-19 in People With Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	31
16	Comparing natural history of early and late onset pediatric multiple sclerosis. Annals of Neurology, 2022, , .	5.3	6
17	Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis Patients: Monocentric Case Series and Systematic Review of the Literature. Journal of Clinical Medicine, 2022, 11, 942.	2.4	5
18	Immunological Subsets Characterization in Newly Diagnosed Relapsingâ€“Remitting Multiple Sclerosis. Frontiers in Immunology, 2022, 13, 819136.	4.8	5

#	Article	IF	Citations
19	Natalizumab treatment and pregnancy in multiple sclerosis: A reappraisal of maternal and infant outcomes after 6â€‰years. Multiple Sclerosis Journal, 2022, 28, 2137-2141.	3.0	3
20	Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study. Brain, 2022, 145, 2796-2805.	7.6	38
21	Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS. Multiple Sclerosis Journal, 2022, , 135245852210845.	3.0	2
22	Paediatric Multiple Sclerosis: A Scoping Review of Patientsâ€™ and Parentsâ€™ Perspectives. Children, 2022, 9, 11.	1.5	3
23	Long-term Cognitive Outcomes and Socioprofessional Attainment in People With Multiple Sclerosis With Childhood Onset. Neurology, 2022, 98, e1626-e1636.	1.1	7
24	Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial. Lancet Neurology, The, 2022, 21, 608-619.	10.2	44
25	Multiple Sclerosis Progressive Courses: A Clinical Cohort Long-Term Disability Progression Study. Value in Health, 2022, 25, 1489-1498.	0.3	2
26	Stopping Interferon Beta 1b Does Not Influence the Risk of Disability Accrual in Non-Active SPMS: Results from an Italian Real-World Study. International Journal of Environmental Research and Public Health, 2022, 19, 6069.	2.6	1
27	A realâ€world evidence study of nabiximols in multiple sclerosis patients with resistant spasticity: Analysis in relation to the newly described â€˜spasticityâ€plus syndromeâ€™. European Journal of Neurology, 2022, 29, 2744-2753.	3.3	10
28	A multiparametric score for assessing the individual risk of severe Covid-19 among patients with Multiple Sclerosis. Multiple Sclerosis and Related Disorders, 2022, 63, 103909.	2.0	4
29	Early use of high-efficacy diseaseâ€‘modifying therapies makes the difference in people with multiple sclerosis: an expert opinion. Journal of Neurology, 2022, 269, 5382-5394.	3.6	32
30	Patients with multiple sclerosis: a burden and cost of illness study. Journal of Neurology, 2022, 269, 5127-5135.	3.6	11
31	Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies. Multiple Sclerosis Journal, 2022, 28, 2106-2111.	3.0	30
32	Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar. Multiple Sclerosis and Related Disorders, 2022, 66, 104025.	2.0	15
33	Oral nomegestrol acetate and transdermal 17-beta-estradiol for preventing post-partum relapses in multiple sclerosis: The POPARTMUS study. Multiple Sclerosis Journal, 2021, 27, 1458-1463.	3.0	8
34	An update on idiopathic intracranial hypertension in adults: a look at pathophysiology, diagnostic approach and management. Journal of Neurology, 2021, 268, 3249-3268.	3.6	36
35	The Dysphagia in Multiple Sclerosis Questionnaire Correlates with Fiber-Optic Endoscopic Examination for Detecting Swallowing Deficits in MS. Dysphagia, 2021, 36, 192-197.	1.8	10
36	Detection of disability worsening in relapsingâ€remitting multiple sclerosis patients: a realâ€world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register. European Journal of Neurology, 2021, 28, 567-578.	3.3	6

#	Article	IF	Citations
37	Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors. Multiple Sclerosis Journal, 2021, 27, 430-438.	3.0	19
38	The Contribution of Illness Beliefs, Coping Strategies, and Social Support to Perceived Physical Health and Fatigue in Multiple Sclerosis. Journal of Clinical Psychology in Medical Settings, 2021, 28, 149-160.	1.4	17
39	Exploring polypharmacy phenomenon in newly diagnosed relapsingâ€“remitting multiple sclerosis: a cohort ambispective single-centre study. Therapeutic Advances in Chronic Disease, 2021, 12, 204062232098312.	2.5	16
40	Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110195.	3.5	48
41	Determinants of therapeutic lag in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1838-1851.	3.0	3
42	Diseaseâ€Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. Annals of Neurology, 2021, 89, 780-789.	5.3	370
43	Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register. Neurotherapeutics, 2021, 18, 905-919.	4.4	9
44	Longâ€Term Safety and Efficacy of Eculizumab in Aquaporinâ€4 <scp>IgGâ€Positive NMOSD</scp>. Annals of Neurology, 2021, 89, 1088-1098.	5.3	55
45	Therapeutic recommendations and seasonal influenza vaccine for multiple sclerosis patients in treatment with ocrelizumab: an expert consensus. Journal of Neurology, 2021, 268, 1540-1543.	3.6	4
46	Living with severe multiple sclerosis: Cost-effectiveness of a palliative care intervention and cost of illness study. Multiple Sclerosis and Related Disorders, 2021, 49, 102756.	2.0	2
47	Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis. Neurology, 2021, 96, .	1.1	41
48	Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study. Neurotherapeutics, 2021, 18, 1166-1174.	4.4	24
49	Male fertility in relapsing-remitting multiple sclerosis patients treated with natalizumab and ocrelizumab: A prospective case-control study. Multiple Sclerosis Journal, 2021, 27, 2284-2287.	3.0	8
50	Identifying the Distinct Cognitive Phenotypes in Multiple Sclerosis. JAMA Neurology, 2021, 78, 414.	9.0	86
51	Early-Onset Alcohol Dependence and Multiple Sclerosis: Diagnostic Challenges. International Journal of Environmental Research and Public Health, 2021, 18, 5588.	2.6	5
52	Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis. JAMA Neurology, 2021, 78, 726.	9.0	26
53	Firstâ€line therapies in lateâ€onset multiple sclerosis: An Italian registry study. European Journal of Neurology, 2021, 28, 4117-4123.	3.3	17
54	DMTs and Covidâ€19 severity in MS: a pooled analysis from Italy and France. Annals of Clinical and Translational Neurology, 2021, 8, 1738-1744.	3.7	86

#	Article	IF	Citations
55	004â€...Pregnancy-related relapse in natalizumab, fingolimod and dimethyl fumarate-treated women with multiple sclerosis. , 2021, , .		0
56	Clinical characteristics of middle-aged and older patients with MS treated with interferon beta-1b: post-hoc analysis of a 2-year, prospective, international, observational study. BMC Neurology, 2021, 21, 324.	1.8	8
57	Study protocol on advance care planning in multiple sclerosis (ConCure-SM): intervention construction and multicentre feasibility trial. BMJ Open, 2021, 11, e052012.	1.9	4
58	Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of <scp>REGAIN</scp> and its extension study. Muscle and Nerve, 2021, 64, 662-669.	2.2	11
59	Italian translation and psychometric validation of the ABILHAND-26 and its correlation with upper limb objective and subjective measures in multiple sclerosis subjects. Multiple Sclerosis and Related Disorders, 2021, 55, 103160.	2.0	3
60	Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registry. Journal of the Neurological Sciences, 2021, 430, 118067.	0.6	9
61	Multiple Sclerosis, COVID-19 and Vaccines: Making the Point. Neurology and Therapy, 2021, 10, 627-649.	3.2	9
62	Natalizumab administration in multiple sclerosis patients during active SARS-CoV-2 infection: a case series. BMC Neurology, 2021, 21, 462.	1.8	4
63	Lack of association between Toxocara canis and multiple sclerosis: A population-based caseâ€“control study. Multiple Sclerosis Journal, 2020, 26, 258-259.	3.0	3
64	Illness perceptions and psychological adjustment among persons with multiple sclerosis: the mediating role of coping strategies and social support. Disability and Rehabilitation, 2020, 42, 3780-3792.	1.8	17
65	Lack of evidence for Toxocara infection in Italian myelitis patients. Neurological Sciences, 2020, 41, 239-241.	1.9	2
66	Italian consensus on treatment of spasticity in multiple sclerosis. European Journal of Neurology, 2020, 27, 445-453.	3.3	20
67	The caring experience in multiple sclerosis: Caregiving tasks, coping strategies and psychological wellâ€being. Health and Social Care in the Community, 2020, 28, 236-246.	1.6	17
68	An â€œall-wheel driveâ€•proposal to accelerate clinical research in common and rare neurological diseases. Neurological Sciences, 2020, 41, 789-793.	1.9	0
69	Prevalence of dysphagia in a consecutive cohort of subjects with MS using fibre-optic endoscopy. Neurological Sciences, 2020, 41, 1075-1079.	1.9	13
70	Incidence of multiple sclerosis in the province of Catania. A geo-epidemiological study. Environmental Research, 2020, 182, 109022.	7.5	10
71	Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders, 2020, 38, 101868.	2.0	29
72	Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1297-1303.	1.9	27

#	Article	IF	Citations
73	Treatment response score to glatiramer acetate or interferon beta-1a. Neurology, 2020, 96, 10.1212/WNL.0000000000010991.	1.1	6
74	Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 46, 102492.	2.0	20
75	Mental health status of relapsing-remitting multiple sclerosis Italian patients returning to work soon after the easing of lockdown during COVID-19 pandemic: A monocentric experience. Multiple Sclerosis and Related Disorders, 2020, 46, 102561.	2.0	24
76	Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: a 18-month multicentre study. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 914-920.	1.9	5
77	Natalizumab is associated with early improvement of working ability in relapsing-remitting multiple sclerosis patients: WANT observational study results. Neurological Sciences, 2020, 42, 2837-2845.	1.9	11
78	Gonadal Steroids and Sperm Quality in a Cohort of Relapsing Remitting Multiple Sclerosis: A Case-Control Study. Frontiers in Neurology, 2020, 11, 756.	2.4	6
79	Delay from treatment start to full effect of immunotherapies for multiple sclerosis. Brain, 2020, 143, 2742-2756.	7.6	24
80	Comparing 16 Different Dualâ€“Tasking Paradigms in Individuals With Multiple Sclerosis and Healthy Controls: Working Memory Tasks Indicate Cognitiveâ€“Motor Interference. Frontiers in Neurology, 2020, 11, 918.	2.4	13
81	Reply to Comment on â€œEnvironmental and Occupational Risk Factors of Amyotrophic Lateral Sclerosis: A Population-Based Case-Control Studyâ€• International Journal of Environmental Research and Public Health, 2020, 17, 6492.	2.6	1
82	Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis. Brain, 2020, 143, 3013-3024.	7.6	53
83	Objective evaluation of Nintendo Wii Fit Plus balance program training on postural stability in Multiple Sclerosis patients: a pilot study. International Journal of Rehabilitation Research, 2020, 43, 199-205.	1.3	6
84	Toxoplasma gondii and multiple sclerosis: a population-based caseâ€“control study. Scientific Reports, 2020, 10, 18855.	3.3	12
85	BetaEval Global: Prospective, Multinational, Observational Cohort Study of Patients Using BETACONNECT^{Â®} . Patient Preference and Adherence, 2020, Volume 14, 771-779.	1.8	4
86	Pharmacotherapeutic management of lower urinary tract symptoms in Multiple Sclerosis patients. Expert Opinion on Pharmacotherapy, 2020, 21, 1449-1454.	1.8	11
87	EAN Guideline on Palliative Care of People with Severe, Progressive Multiple Sclerosis. Journal of Palliative Medicine, 2020, 23, 1426-1443.	1.1	13
88	EAN guideline on palliative care of people with severe, progressive multiple sclerosis. European Journal of Neurology, 2020, 27, 1510-1529.	3.3	23
89	Palliative care in multiple sclerosis: European guideline. Multiple Sclerosis Journal, 2020, 26, 1009-1011.	3.0	2
90	Efficacy of levetiracetam on upper limb movement in multiple sclerosis patients with cerebellar signs: a multicenter doubleâ€blind, placeboâ€controlled, crossover study. European Journal of Neurology, 2020, 27, 2209-2216.	3.3	12

#	Article	IF	Citations
91	Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis. Journal of Neurology, 2020, 267, 3008-3020.	3.6	19
92	Pregnancy and the Postpartum Period in Women With Relapsing-Remitting Multiple Sclerosis Treated With Old and New Disease-Modifying Treatments: A Real-World Multicenter Experience. Frontiers in Neurology, 2020, 11, 105.	2.4	8
93	Administration of subcutaneous interferon beta 1a in the evening: data from RELIEF study. Journal of Neurology, 2020, 267, 1812-1823.	3.6	3
94	Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis. Clinical Drug Investigation, 2020, 40, 319-326.	2.2	5
95	CSF neurotoxic metals/metalloids levels in amyotrophic lateral sclerosis patients: comparison between bulbar and spinal onset. Environmental Research, 2020, 188, 109820.	7.5	17
96	Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS). Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642092268.	3.5	30
97	Box and block test, hand grip strength and nineâ€hole peg test: correlations between three upper limb objective measures in multiple sclerosis. European Journal of Neurology, 2020, 27, 2523-2530.	3.3	18
98	Italian validation of the caregiving tasks in multiple sclerosis scale (CTiMSS). Neurological Sciences, 2020, 41, 1881-1889.	1.9	0
99	Italian translation and psychometric validation of the Manual Ability Measure-36 (MAM-36) and its correlation with an objective measure of upper limb function in patients with multiple sclerosis. Neurological Sciences, 2020, 41, 1539-1546.	1.9	9
100	Immunosuppression in relapsing remitting multiple sclerosis: moving towards personalized treatment. Expert Review of Neurotherapeutics, 2020, 20, 771-782.	2.8	6
101	An update on the pharmacological management of pain in patients with multiple sclerosis. Expert Opinion on Pharmacotherapy, 2020, 21, 2249-2263.	1.8	12
102	Listening to the neurological teams for multiple sclerosis: the SMART project. Neurological Sciences, 2020, 41, 2231-2240.	1.9	6
103	Changes in Anti-JCV Antibody Status in a Large Population of Multiple Sclerosis Patients Treated with Natalizumab. CNS Drugs, 2020, 34, 535-543.	5.9	6
104	Environmental and Occupational Risk Factors of Amyotrophic Lateral Sclerosis: A Population-Based Case-Control Study. International Journal of Environmental Research and Public Health, 2020, 17, 2882.	2.6	42
105	Effects of THC/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter study. Neurological Sciences, 2020, 41, 2905-2913.	1.9	12
106	Clinical and patient determinants of changing therapy in relapsing-remitting multiple sclerosis (SWITCH study). Multiple Sclerosis and Related Disorders, 2020, 42, 102124.	2.0	18
107	Clinical and Lifestyle Factors and Risk of Amyotrophic Lateral Sclerosis: A Population-Based Case-Control Study. International Journal of Environmental Research and Public Health, 2020, 17, 857.	2.6	38
108	A method to compare prospective and historical cohorts to evaluate drug effects. Application to the analysis of early treatment effectiveness of intramuscular interferon-Î²1a in multiple sclerosis patients. Multiple Sclerosis and Related Disorders, 2020, 40, 101952.	2.0	0

#	Article	IF	Citations
109	Patient and caregiver involvement in the formulation of guideline questions: findings from the European Academy of Neurology guideline on palliative care of people with severe multiple sclerosis. European Journal of Neurology, 2019, 26, 41-50.	3.3	27
110	eMSQOL-29: Prospective validation of the abbreviated, electronic version of MSQOL-54. Multiple Sclerosis Journal, 2019, 25, 856-866.	3.0	11
111	Prevalence and Incidence of Multiple Sclerosis in the City of Biancavilla. Neuroepidemiology, 2019, 53, 108-114.	2.3	6
112	An update on the safety of treating relapsing-remitting multiple sclerosis. Expert Opinion on Drug Safety, 2019, 18, 925-948.	2.4	13
113	Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. Lancet Neurology, The, 2019, 18, 845-856.	10.2	110
114	Are oligoclonal bands associated to lower retinal layer thickness at the time of relapsing remitting multiple sclerosis diagnosis? Evidence from an exploratory study. Autoimmunity Reviews, 2019, 18, 102365.	5.8	1
115	Examining the validity of the multiple-sclerosis walking scale-12 with Rasch analysis: Results from an Italian study. Multiple Sclerosis and Related Disorders, 2019, 36, 101400.	2.0	8
116	Conversion to Secondary Progressive Multiple Sclerosis: Patient Awareness and Needs. Results From an Online Survey in Italy and Germany. Frontiers in Neurology, 2019, 10, 916.	2.4	21
117	Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register. Journal of Neurology, 2019, 266, 3098-3107.	3.6	1
118	Cardiovascular autonomic individual profile of relapsing-remitting multiple sclerosis patients and risk of extending cardiac monitoring after first dose fingolimod. Journal of the Neurological Sciences, 2019, 405, 116423.	0.6	6
119	The Neutrophil-to-Lymphocyte Ratio is Related to Disease Activity in Relapsing Remitting Multiple Sclerosis. Cells, 2019, 8, 1114.	4.1	40
120	Newest evidence for tetrahydrocannabinol:cannabidiol oromucosal spray from postapproval pragmatic studies. Neurodegenerative Disease Management, 2019, 9, 3-7.	2.2	1
121	Pharmacoeconomics of synthetic therapies for multiple sclerosis. Expert Opinion on Pharmacotherapy, 2019, 20, 1331-1340.	1.8	8
122	Amyotrophic lateral sclerosis spatial epidemiology in the Mount Etna region, Italy. European Journal of Neurology, 2019, 26, e90-e91.	3.3	7
123	Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: Present and future perspectives. Autoimmunity Reviews, 2019, 18, 665-672.	5.8	25
124	Aging with multiple sclerosis: prevalence and profile of cognitive impairment. Neurological Sciences, 2019, 40, 1651-1657.	1.9	39
125	Cancer Risk and Multiple Sclerosis: Evidence From a Large Italian Cohort. Frontiers in Neurology, 2019, 10, 337.	2.4	26
126	Clinical, laboratory features, and prognostic factors in adult acute transverse myelitis: an Italian multicenter study. Neurological Sciences, 2019, 40, 1383-1391.	1.9	11

#	Article	IF	Citations
127	Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. New England Journal of Medicine, 2019, 381, 2114-2124.	27.0	383
128	Retinal Nerve Fiber Layer Thickness and Higher Relapse Frequency May Predict Poor Recovery after Optic Neuritis in MS Patients. Journal of Clinical Medicine, 2019, 8, 2022.	2.4	17
129	Management of dysphagia in multiple sclerosis: current best practice. Expert Review of Gastroenterology and Hepatology, 2019, 13, 47-54.	3.0	20
130	The Italian multiple sclerosis register. Neurological Sciences, 2019, 40, 155-165.	1.9	59
131	Effectiveness and safety of Rituximab in demyelinating diseases spectrum: An Italian experience. Multiple Sclerosis and Related Disorders, 2019, 27, 324-326.	2.0	35
132	Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience. Journal of Neurology, 2019, 266, 411-416.	3.6	20
133	Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS. Multiple Sclerosis Journal, 2019, 25, 591-600.	3.0	13
134	Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study. Multiple Sclerosis Journal, 2019, 25, 399-407.	3.0	38
135	Hopelessness in Multiple Sclerosis: Psychological and Organic Correlates. Journal of Psychiatry and Psychiatric Disorders, 2019, 03, .	0.0	5
136	Lateral switch to IFN beta-1a 44 mcg may be effective as escalation switch to fingolimod in selected persons with relapsing remitting multiple sclerosis: a real-world setting experience. Expert Review of Clinical Pharmacology, 2018, 11, 531-536.	3.1	4
137	Pregnancy decision-making in women with multiple sclerosis treated with natalizumab. Neurology, 2018, 90, e823-e831.	1.1	102
138	Identifying neuropathic pain in patients with multiple sclerosis: a cross-sectional multicenter study using highly specific criteria. Journal of Neurology, 2018, 265, 828-835.	3.6	45
139	Pharmacokinetic drug evaluation of daclizumab for the treatment of relapsing-remitting multiple sclerosis. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 341-352.	3.3	1
140	Standardised Frankincense extract: new possible therapeutic option for patients with relapsing-remitting multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 327-327.	1.9	2
141	Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: Observational study. Multiple Sclerosis Journal, 2018, 24, 167-174.	3.0	18
142	Randomized controlled trial of a home-based palliative approach for people with severe multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 663-674.	3.0	35
143	Patients with paediatric-onset multiple sclerosis are at higher risk of cognitive impairment in adulthood: An Italian collaborative study. Multiple Sclerosis Journal, 2018, 24, 1234-1242.	3.0	33
144	The Cost-effectiveness of SativexÂ®: The Italian Experience Based on " in Resistant Multiple Sclerosis Spasticity: Discontinuation Study in a Large Population of Italian Patients, SA.FE. Study". International Journal of Neurorehabilitation, 2018, 05, .	0.1	0

#	Article	IF	Citations
145	Authorsâ€™ Response to the Letter to the Editor Regarding: A Comprehensive Review on CopemylÂ®. Neurology and Therapy, 2018, 7, 391-393.	3.2	0
146	No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study. Journal of Neurology, 2018, 265, 2851-2860.	3.6	43
147	Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641879640.	3.5	26
148	Static postural control disturbances among the different multiple sclerosis phenotypes: A Neurocom Balance ManagerÂ® evaluation study. Multiple Sclerosis and Related Disorders, 2018, 26, 46-51.	2.0	5
149	Cognitive assessment in multiple sclerosisâ€”an Italian consensus. Neurological Sciences, 2018, 39, 1317-1324.	1.9	37
150	Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy. Journal of the Neurological Sciences, 2018, 391, 72-76.	0.6	22
151	Lateâ€onset and youngâ€onset relapsingâ€remitting multiple sclerosis: evidence from a retrospective longâ€term followâ€up study. European Journal of Neurology, 2018, 25, 1425-1431.	3.3	47
152	Participant perspectives of a home-based palliative approach for people with severe multiple sclerosis: A qualitative study. PLoS ONE, 2018, 13, e0200532.	2.5	9
153	Botulinum Toxin A for Sialorrhoea Associated with Neurological Disorders: Evaluation of the Relationship between Effect of Treatment and the Number of Glands Treated. Toxins, 2018, 10, 55.	3.4	29
154	Cognitive-motor dual-task interference: A systematic review of neural correlates. Neuroscience and Biobehavioral Reviews, 2017, 75, 348-360.	6.1	179
155	Multiple sclerosis and amyotrophic lateral sclerosis: a human leukocyte antigen challenge. Neurological Sciences, 2017, 38, 1501-1503.	1.9	5
156	Prognostic indicators in pediatric clinically isolated syndrome. Annals of Neurology, 2017, 81, 729-739.	5.3	34
157	Can new chemical therapies improve the management of multiple sclerosis in children?. Expert Opinion on Pharmacotherapy, 2017, 18, 45-55.	1.8	1
158	Computer-assisted cognitive rehabilitation on freezing of gait in Parkinsonâ€™s disease: A pilot study. Neuroscience Letters, 2017, 654, 38-41.	2.1	16
159	Migraine causes retinal and choroidal structural changes: evaluation with ocular coherence tomography. Journal of Neurology, 2017, 264, 494-502.	3.6	43
160	Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsingâ€“remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study). Journal of Neurology, 2017, 264, 2436-2449.	3.6	44
161	The clinical value of Coop/Wonca charts in assessment of HRQoL in a large cohort of relapsing-remitting multiple sclerosis patients: Results of a multicenter study. Multiple Sclerosis and Related Disorders, 2017, 17, 154-171.	2.0	4
162	Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurology, The, 2017, 16, 976-986.	10.2	472

#	Article	IF	Citations
163	A multicenter, observational, prospective study of self- and parent-reported quality of life in adolescent multiple sclerosis patients self-administering interferon-Î²1a using RebiSmartâ„¢the FUTURE study. Neurological Sciences, 2017, 38, 1999-2005.	1.9	15
164	Management of pregnancy-related issues in multiple sclerosis patients: the need for an interdisciplinary approach. Neurological Sciences, 2017, 38, 1849-1858.	1.9	30
165	A Comprehensive Review on CopemylÂ®. Neurology and Therapy, 2017, 6, 161-173.	3.2	6
166	Magnetic fields exposure from high-voltage power lines and risk of amyotrophic lateral sclerosis in two Italian populations. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 583-589.	1.7	11
167	Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes. Multiple Sclerosis Journal, 2017, 23, 1258-1267.	3.0	209
168	Palliative care in progressive multiple sclerosis. Expert Review of Neurotherapeutics, 2017, 17, 123-127.	2.8	5
169	Beyond Disease: Happiness, Goals, and Meanings among Persons with Multiple Sclerosis and Their Caregivers. Frontiers in Psychology, 2017, 8, 2216.	2.1	30
170	Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study). PLoS ONE, 2017, 12, e0180651.	2.5	24
171	Pesticide exposure assessed through agricultural crop proximity and risk of amyotrophic lateral sclerosis. Environmental Health, 2017, 16, 91.	4.0	43
172	Offspring Number Does Not Influence Reaching the Disabilityâ€™s Milestones in Multiple Sclerosis: A Seven-Year Follow-Up Study. International Journal of Molecular Sciences, 2016, 17, 234.	4.1	18
173	A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future Perspectives. International Journal of Molecular Sciences, 2016, 17, 1725.	4.1	27
174	Depressive Symptoms Correlate with Disability and Disease Course in Multiple Sclerosis Patients: An Italian Multi-Center Study Using the Beck Depression Inventory. PLoS ONE, 2016, 11, e0160261.	2.5	46
175	Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 944-951.	1.9	88
176	Personalized therapy in multiple sclerosis: state of art and future perspectives. Expert Review of Precision Medicine and Drug Development, 2016, 1, 353-360.	0.7	2
177	Ataxia with vitamin E deficiency caused by a new compound heterozygous mutation. Neurological Sciences, 2016, 37, 1571-1572.	1.9	1
178	Individualized quality of life of severely affected multiple sclerosis patients: practicability and value in comparison with standard inventories. Quality of Life Research, 2016, 25, 2755-2763.	3.1	10
179	Hormone replacement in menopausal women with multiple sclerosis. Neurology, 2016, 87, 1430-1431.	1.1	2
180	Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs. Drug Safety, 2016, 39, 1163-1174.	3.2	35

#	Article	IF	Citations
181	Risk factors in multiple sclerosis: a population-based caseâ€“control study in Sicily. Background and methods. Neurological Sciences, 2016, 37, 1931-1937.	1.9	13
182	When the word doesn't come out: A synthetic overview of dysarthria. Journal of the Neurological Sciences, 2016, 369, 354-360.	0.6	18
183	US health insurance is an obstacle to disease-modifying treatments in MS. Neurology, 2016, 87, 346-347.	1.1	7
184	Extensive bilateral striopallidodentate calcinosis: a 50Âyears history of hypoparathyroidism presenting like a parkinsonian syndrome. Journal of Neurology, 2016, 263, 1876-1879.	3.6	6
185	The heritage of glatiramer acetate and its use in multiple sclerosis. Multiple Sclerosis and Demyelinating Disorders, 2016, 1, .	1.1	14
186	The epidemiology of amyotrophic lateral sclerosis in the Mount Etna region: a possible pathogenic role of volcanogenic metals. European Journal of Neurology, 2016, 23, 964-972.	3.3	34
187	Lateral and escalation therapy in relapsing-remitting multiple sclerosis: a comparative study. Journal of Neurology, 2016, 263, 1802-1809.	3.6	18
188	Low quality of life and psychological wellbeing contrast with moderate perceived burden in carers of people with severe multiple sclerosis. Journal of the Neurological Sciences, 2016, 366, 139-145.	0.6	26
189	Inpatient versus outpatient rehabilitation for multiple sclerosis patients: effects on disability and quality of life. Multiple Sclerosis and Demyelinating Disorders, 2016, 1, .	1.1	10
190	Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study. Journal of Neurology, 2016, 263, 1727-1735.	3.6	45
191	Expression of DNA methylation genes in secondary progressive multiple sclerosis. Journal of Neuroimmunology, 2016, 290, 66-69.	2.3	17
192	Diagnostic tools for assessment of urinary dysfunction in MS patients without urinary disturbances. Neurological Sciences, 2016, 37, 437-442.	1.9	7
193	The cognitive reserve theory in the setting of pediatric-onset multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 1741-1749.	3.0	32
194	Health Authorities Data Collection of THC:CBD Oromucosal Spray (L'Agenzia Italiana del Farmaco Web) Tj ETQq0 0 0 rgBT /Overlock 10	1.4	7
195	Can we define a rehabilitation strategy for cognitive impairment in progressive multiple sclerosis? A critical appraisal. Multiple Sclerosis Journal, 2016, 22, 581-589.	3.0	23
196	Use of herbal remedies by multiple sclerosis patients: a nation-wide survey in Italy. Neurological Sciences, 2016, 37, 613-622.	1.9	14
197	Illness Perception and Well-Being Among Persons with Multiple Sclerosis and Their Caregivers. Journal of Clinical Psychology in Medical Settings, 2016, 23, 33-52.	1.4	39
198	Development of a Short Version of MSQOL-54 Using Factor Analysis and Item Response Theory. PLoS ONE, 2016, 11, e0153466.	2.5	31

#	Article	IF	Citations
199	The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retroprospective Study. PLoS ONE, 2016, 11, e0157721.	2.5	5
200	Disability may influence patient willingness to participate in decision making on first-line therapy in multiple sclerosis. Functional Neurology, 2016, 31, 21-3.	1.3	13
201	Clinical and radiologic rebound after discontinuation of natalizumab therapy in a highly active multiple sclerosis patient was not halted by dimethyl-fumarate: a case report. BMC Neurology, 2015, 15, 252.	1.8	9
202	Lesion Load May Predict Long-Term Cognitive Dysfunction in Multiple Sclerosis Patients. PLoS ONE, 2015, 10, e0120754.	2.5	31
203	Italian Validation of the 12-Item Multiple Sclerosis Walking Scale. Multiple Sclerosis International, 2015, 2015, 1-6.	0.8	12
204	Monoclonal antibody therapy in multiple sclerosis: critical appraisal and new perspectives. Expert Review of Neurotherapeutics, 2015, 15, 251-268.	2.8	4
205	Home-based palliative approach for people with severe multiple sclerosis and their carers: study protocol for a randomized controlled trial. Trials, 2015, 16, 184.	1.6	28
206	Analysis of genes, pathways and networks involved in disease severity and age at onset in primary-progressive multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 1431-1442.	3.0	27
207	Prevalence and incidence of cognitive impairment in multiple sclerosis: a population-based survey in Catania, Sicily. Journal of Neurology, 2015, 262, 923-930.	3.6	46
208	A critical appraisal of daclizumab use as emerging therapy in multiple sclerosis. Expert Opinion on Drug Safety, 2015, 14, 1157-1168.	2.4	3
209	Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal. Expert Review of Neurotherapeutics, 2015, 15, 803-824.	2.8	30
210	Multiple sclerosis: getting personal with induced pluripotent stem cells. Cell Death and Disease, 2015, 6, e1806-e1806.	6.3	17
211	Measuring the cost of cognitive-motor dual tasking during walking in multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 123-131.	3.0	117
212	Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis. Brain, 2015, 138, 3275-3286.	7.6	76
213	Relationship between urodynamic findings and sexual function in multiple sclerosis patients with lower urinary tract dysfunction. European Journal of Neurology, 2015, 22, 485-492.	3.3	19
214	Restless legs syndrome and multiple sclerosis: a population based caseâ^'control study in Catania, Sicily. European Journal of Neurology, 2015, 22, 1018-1021.	3.3	25
215	Association Between the Neurogenic Bladder Symptom Score and Urodynamic Examination in Multiple Sclerosis Patients With Lower Urinary Tract Dysfunction. International Neurourology Journal, 2015, 19, 272-277.	1.2	13
216	Unmet Needs of People with Severe Multiple Sclerosis and Their Carers: Qualitative Findings for a Home-Based Intervention. PLoS ONE, 2014, 9, e109679.	2.5	67

#	Article	IF	Citations
217	Fostering adherence to injectable disease-modifying therapies in multiple sclerosis. Expert Review of Neurotherapeutics, 2014, 14, 1029-1042.	2.8	52
218	Symptoms, Prevalence and Impact of Multiple Sclerosis in Younger Patients: A Multinational Survey. Neuroepidemiology, 2014, 42, 211-218.	2.3	29
219	Determinants of Sexual Impairment in Multiple Sclerosis in Male and Female Patients with Lower Urinary Tract Dysfunction: Results from an Italian Crossâ€Sectional Study. Journal of Sexual Medicine, 2014, 11, 2406-2413.	0.6	30
220	Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 845-850.	1.9	66
221	Clinical and magnetic resonance imaging predictors of disease progression in multiple sclerosis: a nine-year follow-up study. Multiple Sclerosis Journal, 2014, 20, 220-226.	3.0	30
222	Gray Matters in Multiple Sclerosis: Cognitive Impairment and Structural MRI. Multiple Sclerosis International, 2014, 2014, 1-9.	0.8	45
223	The Raoâ€™s Brief Repeatable Battery version B: normative values with age, education and gender corrections in an Italian population. Neurological Sciences, 2014, 35, 79-82.	1.9	31
224	Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group. Neurological Sciences, 2014, 35, 307-316.	1.9	30
225	Pregnancy outcomes in multiple sclerosis patients previously treated with cyclophosphamide. Acta Neurologica Scandinavica, 2014, 130, e41-e44.	2.1	5
226	Genetic burden of common variants in progressive and bout-onset multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 802-811.	3.0	11
227	Neuropsychological features in childhood and juvenile multiple sclerosis. Neurology, 2014, 83, 1432-1438.	1.1	227
228	Subcortical Deep Gray Matter Pathology in Patients with Multiple Sclerosis Is Associated with White Matter Lesion Burden and Atrophy but Not with Cortical Atrophy: A Diffusion Tensor MRI Study. American Journal of Neuroradiology, 2014, 35, 912-919.	2.4	44
229	Is the basic trunk control recovery different between stroke patients with right and left hemiparesis?. NeuroRehabilitation, 2014, 35, 215-220.	1.3	6
230	The coexistence of well- and ill-being in persons with multiple sclerosis, their caregivers and health professionals. Journal of the Neurological Sciences, 2014, 337, 67-73.	0.6	37
231	Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study. BMC Neurology, 2014, 14, 114.	1.8	27
232	Interferon-beta-1a treatment has a positive effect on quality of life of relapsingâ€“remitting multiple sclerosis: Results from a longitudinal study. Journal of the Neurological Sciences, 2014, 337, 180-185.	0.6	9
233	Diffusion tensor MRI alterations of subcortical deep gray matter in clinically isolated syndrome. Journal of the Neurological Sciences, 2014, 338, 128-134.	0.6	20
234	Heme oxygenase-1 expression in peripheral blood mononuclear cells correlates with disease activity in multiple sclerosis. Journal of Neuroimmunology, 2013, 261, 82-86.	2.3	45

#	Article	IF	Citations
235	Cognitive impairment and â€œinvisible symptomsâ€•are not associated with CCSVI in MS. BMC Neurology, 2013, 13, 97.	1.8	6
236	The pharmacokinetics of glatiramer acetate for multiple sclerosis treatment. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 1349-1359.	3.3	19
237	Prevalence of patient-reported dysphagia in multiple sclerosis patients: An Italian multicenter study (using the DYMUS questionnaire). Journal of the Neurological Sciences, 2013, 331, 94-97.	0.6	53
238	Endovascular treatment of CCSVI in patients with multiple sclerosis: clinical outcome of 462 cases. Neurological Sciences, 2013, 34, 1633-1637.	1.9	20
239	Observational case-control study of the prevalence of chronic cerebrospinal venous insufficiency in multiple sclerosis: results from the CoSMo study. Multiple Sclerosis Journal, 2013, 19, 1508-1517.	3.0	42
240	Duloxetine Is Effective in Treating Depression in Multiple Sclerosis Patients. Clinical Neuropharmacology, 2013, 36, 114-116.	0.7	31
241	Adverse events after endovascular treatment of chronic cerebro-spinal venous insufficiency (CCSVI) in patients with multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 961-963.	3.0	17
242	Subcutaneous Interferon Î²-1a May Protect against Cognitive Impairment in Patients with Relapsingâ€“Remitting Multiple Sclerosis: 5-Year Follow-up of the COGIMUS Study. PLoS ONE, 2013, 8, e74111.	2.5	53
243	Multiple Sclerosis in the Mount Etna Region: Possible Role of Volcanogenic Trace Elements. PLoS ONE, 2013, 8, e74259.	2.5	17
244	Aspetti che influenzano lâ€™adesione alla terapia. , 2013, , 81-87.		0
245	Fatigue and its relationships with cognitive functioning and depression in paediatric multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 329-334.	3.0	77
246	Longitudinal changes in social functioning in mildly disabled patients with relapsingâ€“remitting multiple sclerosis receiving subcutaneous interferon Î²-1a: results from the COGIMUS (COGnitive) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	3.1	1
247	Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. BMC Neurology, 2012, 12, 124.	1.8	82
248	Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study. BMC Neurology, 2012, 12, 165.	1.8	78
249	Treatment of cognitive impairment in patients with multiple sclerosis. Expert Opinion on Investigational Drugs, 2012, 21, 1679-1699.	4.1	26
250	Multiple Sclerosis and CCSVI: A Population-Based Case Control Study. PLoS ONE, 2012, 7, e41227.	2.5	25
251	Frequency and severity of headache is worsened by Interferon-Î² therapy in patients with multiple sclerosis. Acta Neurologica Scandinavica, 2012, 125, 91-95.	2.1	38
252	Serum and CSF N-acetyl aspartate levels differ in multiple sclerosis and neuromyelitis optica. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 1355-1359.	1.9	29

#	Article	IF	Citations
253	The Global Adherence Project (GAP): a multicenter observational study on adherence to diseaseâ€modifying therapies in patients with relapsingâ€remitting multiple sclerosis. European Journal of Neurology, 2011, 18, 69-77.	3.3	299
254	Botulinum toxin improves dysphagia associated with multiple sclerosis. European Journal of Neurology, 2011, 18, 486-490.	3.3	48
255	Clinical features of Sjogrenâ€™s syndrome in patients with multiple sclerosis. Acta Neurologica Scandinavica, 2011, 124, 109-114.	2.1	18
256	Multiple sclerosis in Italy: cost-of-illness study. Neurological Sciences, 2011, 32, 787-794.	1.9	33
257	Recommendations for the management of urinary disorders in multiple sclerosis: a consensus of the Italian Multiple Sclerosis Study Group. Neurological Sciences, 2011, 32, 1223-1231.	1.9	43
258	Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving interferon Î²-1a in the COGnitive Impairment in MUltiple Sclerosis (COGIMUS) study. BMC Neurology, 2011, 11, 125.	1.8	11
259	Increasing frequency of multiple sclerosis in Catania, Sicily: a 30-year survey. Multiple Sclerosis Journal, 2011, 17, 273-280.	3.0	36
260	Sporadic motor neuron disease in a familial novel SOD1 mutation: Incomplete penetrance or chance association?. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 220-222.	2.1	7
261	Lights and Shadows of Cyclophosphamide in the Treatment of Multiple Sclerosis. Autoimmune Diseases, 2011, 2011, 1-14.	0.6	31
262	Quality of life, depression and fatigue in mildly disabled patients with relapsingâ€“remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50	3.1	41
263	Breastfeeding is not related to postpartum relapses in multiple sclerosis. Neurology, 2011, 77, 145-150.	1.1	135
264	Psychosocial issue in children and adolescents with multiple sclerosis. Neurological Sciences, 2010, 31, 467-470.	1.9	42
265	Treatment options of cognitive impairment in multiple sclerosis. Neurological Sciences, 2010, 31, 265-269.	1.9	24
266	Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence. Patient Preference and Adherence, 2010, 4, 1.	1.8	146
267	Cognitive and psychosocial features in childhood and juvenile MS. Neurology, 2010, 75, 1134-1140.	1.1	198
268	Lithium carbonate in amyotrophic lateral sclerosis. Neurology, 2010, 75, 619-625.	1.1	90
269	Pregnancy and fetal outcomes after interferon-Î² exposure in multiple sclerosis. Neurology, 2010, 75, 1794-1802.	1.1	142
270	Outcome of psychiatric symptoms presenting at onset of multiple sclerosis: a retrospective study. Multiple Sclerosis Journal, 2010, 16, 742-748.	3.0	63

#	Article	IF	Citations
271	Mutation analysis of the SPG4 gene in Italian patients with pure and complicated forms of spastic paraplegia. Journal of the Neurological Sciences, 2010, 288, 96-100.	0.6	27
272	Effects of immunomodulatory treatment with subcutaneous interferon beta-1a oncognitive decline in mildly disabled patients with relapsingâ€"remitting multiple sclerosis. Multiple Sclerosis Journal, 2010, 16, 68-77.	3.0	89
273	Quality of Life in Patients Affected by Multiple Sclerosis: A Systematic Review. , 2010, , 3769-3783.		1
274	Psychometric properties of the Italian version of the Guy's Neurological Disability Scale. Functional Neurology, 2010, 25, 223-33.	1.3	3
275	Clinical efficacy issues in the treatment of multiple sclerosis: update of natalizumab. ClinicoEconomics and Outcomes Research, 2009, 1, 45.	1.9	2
276	The brief neuropsychological battery for children: a screening tool for cognitive impairment in childhood and juvenile multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 620-626.	3.0	56
277	Cognitive impairment in multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 2-8.	3.0	132
278	Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsingâ€"remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study. Multiple Sclerosis Journal, 2009, 15, 779-788.	3.0	172
279	Subcutaneous interferon beta-1a has a positive effect on cognitive performance in mildly disabled patients with relapsingâ€"remitting multiple sclerosis: 2-year results from the COGIMUS study. Therapeutic Advances in Neurological Disorders, 2009, 2, 67-77.	3.5	11
280	A possible spatial and temporal cluster of multiple sclerosis in the town of Linguaglossa, Sicily: an update. Multiple Sclerosis Journal, 2009, 15, 129-130.	3.0	9
281	Realâ€life impact of early interferonÎ² therapy in relapsing multiple sclerosis. Annals of Neurology, 2009, 66, 513-520.	5.3	132
282	Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience. Neurological Sciences, 2009, 30, 193-199.	1.9	68
283	An exploration of anger phenomenology in multiple sclerosis. European Journal of Neurology, 2009, 16, 1312-1317.	3.3	16
284	Post-marketing of disease modifying drugs in multiple sclerosis: An exploratory analysis of gender effect in interferon beta treatment. Journal of the Neurological Sciences, 2009, 286, 109-113.	0.6	23
285	Variable effects of cyclophosphamide in rodent models of experimental allergic encephalomyelitis. Clinical and Experimental Immunology, 2009, 159, 159-168.	2.6	26
286	Validation of the DYMUS questionnaire for the assessment of dysphagia in multiple sclerosis. Functional Neurology, 2009, 24, 159-62.	1.3	42
287	Is in utero early-exposure to interferon beta a risk factor for pregnancy outcomes in multiple sclerosis?. Journal of Neurology, 2008, 255, 1250-1253.	3.6	74
288	Headache and Multiple Sclerosis: A Population-Based Case-Control Study in Catania, Sicily. Cephalalgia, 2008, 28, 1163-1169.	3.9	64

#	Article	IF	Citations
289	The DYMUS questionnaire for the assessment of dysphagia in multiple sclerosis. Journal of the Neurological Sciences, 2008, 269, 49-53.	0.6	85
290	Cognitive and psychosocial features of childhood and juvenile MS. Neurology, 2008, 70, 1891-1897.	1.1	251
291	Caregiver quality of life in multiple sclerosis: a multicentre Italian study. Multiple Sclerosis Journal, 2007, 13, 412-419.	3.0	78
292	Effects of education level and employment status on HRQoL in early relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 2007, 13, 783-791.	3.0	113
293	Predictors of quality of life among patients with multiple sclerosis: An Italian cross-sectional study. Journal of the Neurological Sciences, 2007, 252, 121-129.	0.6	40
294	The Raoâ€™s Brief Repeatable Battery and Stroop test: normative values with age, education and gender corrections in an Italian population. Multiple Sclerosis Journal, 2006, 12, 787-793.	3.0	343
295	Effects of interferon beta-1a and -1b over time: 6-year results of an observational head-to-head study. Acta Neurologica Scandinavica, 2006, 113, 241-247.	2.1	28
296	Pharmacologic management of spasticity in multiple sclerosis. Neurological Sciences, 2006, 27, s310-s315.	1.9	5
297	Non-pharmacologic interventions for spasticity associated with multiple sclerosis. Neurological Sciences, 2006, 27, s316-s319.	1.9	3
298	Management of swallowing disorders in multiple sclerosis. Neurological Sciences, 2006, 27, s338-s340.	1.9	10
299	A possible spatial and temporal cluster of multiple sclerosis in the town of Linguaglossa, Sicily. Journal of Neurology, 2005, 252, 921-925.	3.6	20
300	The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsingâ€“remitting multiple sclerosis patients. Journal of Neurology, 2005, 252, 1255-1261.	3.6	30
301	Possible increasing risk of multiple sclerosis in Catania, Sicily. Neurology, 2005, 65, 1259-1263.	1.1	46
302	Brain atrophy and lesion load in a large population of patients with multiple sclerosis. Neurology, 2005, 65, 280-285.	1.1	142
303	Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study. Multiple Sclerosis Journal, 2005, 11, 420-424.	3.0	99
304	The prevalence of pain in multiple sclerosis. Neurology, 2004, 63, 919-921.	1.1	274
305	Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon beta. Journal of Neurology, 2004, 251, 1502-1506.	3.6	30
306	A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN. Journal of the Neurological Sciences, 2004, 223, 69-71.	0.6	27

#	Article	IF	Citations
307	Health-related quality of life and depression in an Italian sample of multiple sclerosis patients. Journal of the Neurological Sciences, 2003, 211, 55-62.	0.6	99
308	Increased serum levels of interleukin-18 in patients with multiple sclerosis. Neurology, 2001, 57, 342-344.	1.1	86
309	Prevalence and incidence of multiple sclerosis in Catania, Sicily. Neurology, 2001, 56, 62-66.	1.1	60
310	Combination of cyclophosphamide and interferon-beta halts progression in patients with rapidly transitional multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2001, 71, 404-407.	1.9	49
311	Sodium fusidate (fusidin) ameliorates the course of monophasic experimental allergic encephalomyelitis in the Lewis rat. Multiple Sclerosis Journal, 2001, 7, 101-104.	3.0	8
312	The Antiinflammatory Cytokine Interleukin-13 is not Detectable in the Circulation of Multiple Sclerosis Patients and is not Inducible by Interferon-Î² 1b Treatment, that Neither Modifies its ex vivo Secretion from Peripheral Blood Mononuclear Cells. Autoimmunity, 2000, 32, 265-270.	2.6	4
313	Neuropsychological, neuroradiological and clinical findings in multiple sclerosis. A 3 year follow-up study. European Journal of Neurology, 1998, 5, 283-286.	3.3	32
314	Blood levels of transforming growth factor-beta 1 (TGF-Î²1) are elevated in both relapsing remitting and chronic progressive multiple sclerosis (MS) patients and are further augmented by treatment with interferon-beta 1b (IFN-Î²1b). Clinical and Experimental Immunology, 1998, 113, 96-99.	2.6	72
315	CIRCULATING SERUM LEVELS OF IL-1ra IN PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS ARE NORMAL DURING REMISSION PHASES BUT SIGNIFICANTLY INCREASED EITHER DURING EXACERBATIONS OR IN RESPONSE TO IFN-Î² TREATMENT. Cytokine, 1996, 8, 395-400.	3.2	81
316	Elevated serum levels of interleukin-12 in chronic progressive multiple sclerosis. Journal of Neuroimmunology, 1996, 70, 87-90.	2.3	112
317	Drug-induced parkinsonism: prevalence, clinical features and follow-up study in three Sicilian communities. Journal of Neurology, 1996, 243, 293-301.	3.6	3
318	Disease Modifying Therapies and COVID-19 Severity in Multiple Sclerosis. SSRN Electronic Journal, 0, , .	0.4	31
319	Spasticity and Dystonia: A Brief Review. , 0, , .		0